Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 3/20 | 0.52 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.52 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | GLB1 | P16278 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6663038 | 1.00 | GNAI3 (0.52) | GNAI3GNAO1GNAI1SIGMAR1GLB1 | |
| SCHEMBL6529493 | 0.92 | GNAI3 (0.61) | GNAI3GNAO1GNAI1SIGMAR1 | |
| SCHEMBL18538874 | 0.91 | GNAI3 (0.58) | GNAI3GNAO1GNAI1SIGMAR1GLB1 | |
| SCHEMBL1537447 | 0.91 | — | — | |
| SCHEMBL2318272 | 0.91 | GNAI3 (0.58) | GNAI3GNAO1GNAI1SIGMAR1GLB1 | |
| SCHEMBL1043894 | 0.91 | GNAI3 (0.58) | GNAI3GNAO1GNAI1SIGMAR1GLB1 | |
| SCHEMBL11737731 | 0.90 | GNAO1 (0.65) | GNAI3GNAO1GNAI1SIGMAR1 | |
| SCHEMBL11733529 | 0.90 | GNAO1 (0.65) | GNAI3GNAO1GNAI1SIGMAR1 | |
| SCHEMBL11736163 | 0.90 | GNAO1 (0.65) | GNAI3GNAO1GNAI1SIGMAR1 | |
| SCHEMBL10254568 | 0.90 | GNAO1 (0.65) | GNAI3GNAO1GNAI1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105449276-B | A kind of piperazine ionic liquid lithium-ion battery electrolytes | 中南大学 | 2018-07-17 | — | — | CN | claimed |
| CN-105449276-A | Piperazine ionic liquid electrolyte of lithium ion battery | UNIV CENTRAL SOUTH | 2016-03-30 | — | — | CN | claimed |
| EP-4400499-A1 | GLUTARIMIDE COMPOUND AND USE THEREOF | Medshine Discovery Inc. (CN) | 2024-07-17 | — | — | EP | disclosed |
| WO-2023242598-A1 | BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LIMITED (GB) | 2023-12-21 | — | — | WO | disclosed |
| US-20230312498-A1 | NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2023-10-05 | — | — | US | disclosed |
| US-11730720-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| US-11718595-B2 | Non-ATP/catalytic site p38 Mitogen Activated Protein Kinase inhibitors | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-08-08 | — | — | US | disclosed |
| WO-2023092242-A1 | MULTI-MOTIF DENDRONS AND THEIR SUPRAMOLECULAR STRUCTURES AND USES THEREOF | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023083194-A1 | WEE1 PROTEIN KINASE DEGRADATION AGENT AND USE THEREOF | 杭州格博生物医药有限公司 | 2023-05-19 | — | — | WO | disclosed |
| WO-2023019181-A1 | SARS-COV-2 LIPID NANOPARTICLE VACCINE FORMULATIONS | MODERNATX, INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023003862-A1 | CXCR4 MODULATORS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2023-01-26 | — | — | WO | disclosed |
| US-20090312319-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE | 2009-12-17 | — | — | US | disclosed |
| US-7612064-B2 | Sulfopyrroles | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-03 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
| US-7384952-B2 | Pyrazolopyrimidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-06-10 | — | — | US | disclosed |
| US-7384952-B2 | Pyrazolopyrimidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-06-10 | — | — | US | disclosed |
| EP-1857459-A2 | Pyrazolopyrimidine compound and a process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 2007-11-21 | — | — | EP | disclosed |
| US-20070232604-A1 | receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors | AMBIT BIOSCIENCES CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-20070060570-A1 | Sulfopyrroles | TALEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-15 | — | — | US | disclosed |
| US-4992150-A | Telomer with alpha-olefin;oil and fuel additive | NIPPON OIL CO, LTD. (JP) | 1991-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312319-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | GNAI3 272/4885GNAO1 718/4885GNAI1 288/4885 |
| US-20070060570-A1 | Sulfopyrroles | TYK2, ARSA, SULT2A1 | GNAI3 1361/4885GNAO1 2171/4885GNAI1 1366/4885 |
| US-20230312498-A1 | NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | MAPK1, MAPK8, MAPK4 | GNAI3 1151/4885GNAO1 1273/4885GNAI1 740/4885 |
| US-11730720-B2 | ALK5 inhibitors | ALK, ACVR1, ACVRL1 | GNAI3 512/4885GNAO1 1270/4885GNAI1 715/4885 |
| US-20070232604-A1 | receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors | GRK2, GRK3, BLK | GNAI3 674/4885GNAO1 1526/4885GNAI1 816/4885 |
| US-11718595-B2 | Non-ATP/catalytic site p38 Mitogen Activated Protein Kinase inhibitors | MAPK1, MAPK8, MAPK4 | GNAI3 1151/4885GNAO1 1273/4885GNAI1 740/4885 |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | HPGDS, HPGD, DPYD | GNAI3 1849/4885GNAO1 2920/4885GNAI1 1958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.